Earnings Feed
Start Free
Home/Filings/4/0001209191-14-020007
4//SEC Filing

ARATANA THERAPEUTICS, INC. 4

Accession 0001209191-14-020007

CIK 0001509190operating
View on SEC.govCompany Profile

Filed

Mar 11, 8:00 PM ET

Accepted

Mar 12, 6:55 PM ET

Size

21.4 KB

Accession

0001209191-14-020007

Insider Transaction Report

Form 4
Period: 2014-03-10
ARATANA THERAPEUTICS, INC.PETX
MPM BIOVENTURES V, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By LLC)
    37,117

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937
EVNIN LUKE
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By LLC)
    37,117
GADICKE ANSBERT
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By LLC)
    37,117

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767
KAILIAN VAUGHN M
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By LLC)
    37,117
Foley Todd
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By LLC)
    37,117

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937
MPM ASSET MANAGEMENT INVESTORS BV5 LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By LLC)
    37,117
Scopa James Paul
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By LLC)
    37,117
MPM BIOVENTURES V GP LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By LLC)
    37,117
MPM BIOVENTURES V LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2014-03-10$20.02/sh−600,000$12,012,000→ 2,751,048 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: By Luke Evnin)
    38,386

  • Common Stock

    (indirect: By James Paul Scopa)
    22,767

  • Common Stock

    (indirect: By Vaughn Kailian)
    17,937

  • Common Stock

    (indirect: By LLC)
    37,117
Footnotes (4)
  • [F1]The shares were sold as follows: 577,520 by MPM BioVentures V, L.P. ("BV V") and 22,480 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa and Todd Foley are the members of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  • [F2]The shares are held as follows: 2,647,974 by BV V and 103,074 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  • [F3]Includes 2,627 shares held by The Vaughn and Patricia Kailian Revocable Trust u/a/dtd 12/18/1992, of which the Reporting Person is trustee.
  • [F4]Medical Portfolio Management LLC ("MPM Medical") is the managing member of MPM Capital LLC, and Messrs. Evnin and Gadicke are members of MPM Medical. Messrs. Evnin and Gadicke disclaim beneficial ownership of the shares held by MPM Capital LLC except to the extent of their respective pecuniary interests therein.

Documents

1 file

Issuer

ARATANA THERAPEUTICS, INC.

CIK 0001509190

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001509190

Filing Metadata

Form type
4
Filed
Mar 11, 8:00 PM ET
Accepted
Mar 12, 6:55 PM ET
Size
21.4 KB
View on SEC.gov